CD80 and rheumatoid arthritis: Abatacept and its sister molecule belatacept bind to B7-1 and B7-2 on antigen-presenting cells, thereby blocking T cell activation, and are currently licensed for the treatment of rheumatoid arthritis and the prevention of rejection in kidney transplantation [12–14].